Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-23 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-09-18	€0.8370	+1.09%
26-09-17	€0.8280	+8.95%
26-09-16	€0.7600	-4.28%
26-09-15	€0.7940	-2.10%
26-09-14	€0.8110	-0.37%

Delayed Quote Börse Stuttgart

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8600EUR

Average target price

1.100EUR

Spread / Average Target

+27.91%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Börse Stuttgart 15:31:09 2026-09-18 EDT			5-day change	1st Jan Change
0.8370 ^EUR	+1.09%		+2.83%	-5.32%

09-08	Transgene Expands ProBioGen Partnership With Additional License	MT
09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE

Market Cap	236M 270M 222M 202M 378M 25.92B 380M 2.66B 1.03B 13.18B 1.01B 992M 42.4B	P/E 2026 *	-6.14x	P/E 2027 *	-3.91x
Enterprise Value	166M 191M 157M 143M 267M 18.3B 268M 1.88B 726M 9.31B 717M 701M 29.94B	EV / Sales 2026 *	23.1x	EV / Sales 2027 *	31.6x
Free-Float	19.4%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
CBOE	TNGp	Real-time
Boerse Muenchen	TGNA	Real-time
OTC Markets	TRGNF	Delayed
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Börse Stuttgart	TGNA	Delayed

09-08	Transgene Expands ProBioGen Partnership With Additional License	MT
09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-02	Transgene: no cases of recurrence at three years among patients treated with TG4050
09-02	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene
06-25	Positive Preclinical Data for a Transgene Vaccine
06-25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
06-22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
06-22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI

Transgene Stock Börse Stuttgart

Stocks

TGNA

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news: Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Price Extremes

Managers and Directors: Transgene

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

06-25	Oddo BHF Stays Positive on Transgene
04-07	Transgene stands out following licensing agreement with NEC Bio
11-27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
25-10-13	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
25-09-18	Transgene: analysts reiterate their recommendations after results

09-08	Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line	GL
09-02	Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications	GL
07-07	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026	GL
06-25	Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026	GL
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	GL

09-18	Agenda Zonebourse des résultats de sociétés : semaine du 21 au 25 septembre 2026
09-08	Bourse : Eurazeo finance Mistral, les opérateurs européens veulent riposter à Starlink, Anthropic renoncerait à Decart
09-08	Transgene étend sa collaboration avec ProBioGen
09-08	Le yen s'énerve et anime un début de semaine soporifique
09-08	Transgene étend son partenariat stratégique avec ProBioGen par un nouvel accord de licence pour la lignée cellulaire AGE1.CR.pIX

1 week	+2.83%
Current month	+14.34%
1 month	+25.86%
3 months	+17.56%
6 months	+14.97%
Current year	-5.32%

1 week	0.75	0.88
1 month	0.62	0.96
3 years	0.52	1.79
5 years	0.52	2.92
10 years	0.52	3.51

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	2023-05-31
Lucie Larguier DFI	Director of Finance/CFO	-	2024-03-26
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	2025-04-01

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	2010-07-26
Jean-Luc Bélingard BRD	Director/Board Member	76	2013-06-18
Alain Mérieux BRD	Director/Board Member	88	2006-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	+1.09%	+2.83%	-27.53%	-53.08%	270M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+48.93%	+97.53%	70.88B
ARGENX SE	+0.39%	+2.06%	+39.38%	+78.27%	62.49B
INSMED INCORPORATED	-3.21%	-7.27%	-17.10%	+356.10%	26.21B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+33.27%	+16.01%	26.34B
BIONTECH SE	-2.64%	-0.69%	-0.17%	-13.01%	24.13B
GENMAB A/S	+0.71%	+8.03%	+25.03%	-12.74%	20.72B
PHARMAESSENTIA CORPORATION	-1.26%	-7.81%	+156.15%	+320.43%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+45.54%	+172.46%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-5.51%	+849.47%	14.25B
Average	-0.59%	+1.65%	+29.80%	+181.14%	30.54B
Weighted average by Cap.	-0.47%	+1.44%	+35.78%	+147.17%

	2026 *	2027 *
Net sales	7.2M 8.26M 6.8M 6.17M 11.57M 792M 11.61M 81.44M 31.43M 403M 31.02M 30.33M 1.3B	7.2M 8.26M 6.8M 6.17M 11.57M 792M 11.61M 81.44M 31.43M 403M 31.02M 30.33M 1.3B
Net income	-38.2M -43.81M -36.07M -32.75M -61.37M -4.2B -61.62M -432M -167M -2.14B -165M -161M -6.88B	-61.6M -70.64M -58.16M -52.82M -98.96M -6.78B -99.37M -697M -269M -3.45B -265M -259M -11.09B
Net Debt	-69.2M -79.36M -65.34M -59.33M -111M -7.61B -112M -783M -302M -3.87B -298M -291M -12.46B	-7.7M -8.83M -7.27M -6.6M -12.37M -847M -12.42M -87.09M -33.61M -431M -33.17M -32.43M -1.39B